Kinase target profile of inhibitors that can be used for the treatment of chronic myeloid leukemia (CML).
| TKI . | ABL . | ABLT315I . | Kit . | PDGFR . | SRC . | Aurora . | Others . |
|---|---|---|---|---|---|---|---|
| +, weak/moderate inhibition; ++, moderate/strong inhibition; +++, very strong inhibition. | |||||||
| Abbreviations: TKI, tyrosine kinase inhibitor; NR, not reported; LCK, lymphocyte-specific protein tyrosine kinase; LYN, Lck/Yes-related novel tyrosine kinase. | |||||||
| Imatinib | + | - | ++ | ++ | LCK | - | + |
| Nilotinib | ++ | - | + | + | - | - | - |
| Dasatinib | +++ | - | ++ | ++ | +++ | - | +++ |
| Bosutinib | ++ | - | - | - | +++ | - | + |
| INNO-406 | ++ | - | - | ++ | LYN | - | NR |
| MK-0457 | + | + | - | - | - | +++ | NR |
| XL228 | +++ | +++ | NR | NR | NR | +++ | NR |
| PHA-739358 | ++ | ++ | + | NR | + | +++ | + |
| AP24534 | +++ | +++ | NR | NR | NR | NR | NR |
| SGX393 | +++ | +++ | - | - | LCK | - | + |
| DC-2036 | +++ | +++ | NR | NR | ++ | NR | NR |
| TKI . | ABL . | ABLT315I . | Kit . | PDGFR . | SRC . | Aurora . | Others . |
|---|---|---|---|---|---|---|---|
| +, weak/moderate inhibition; ++, moderate/strong inhibition; +++, very strong inhibition. | |||||||
| Abbreviations: TKI, tyrosine kinase inhibitor; NR, not reported; LCK, lymphocyte-specific protein tyrosine kinase; LYN, Lck/Yes-related novel tyrosine kinase. | |||||||
| Imatinib | + | - | ++ | ++ | LCK | - | + |
| Nilotinib | ++ | - | + | + | - | - | - |
| Dasatinib | +++ | - | ++ | ++ | +++ | - | +++ |
| Bosutinib | ++ | - | - | - | +++ | - | + |
| INNO-406 | ++ | - | - | ++ | LYN | - | NR |
| MK-0457 | + | + | - | - | - | +++ | NR |
| XL228 | +++ | +++ | NR | NR | NR | +++ | NR |
| PHA-739358 | ++ | ++ | + | NR | + | +++ | + |
| AP24534 | +++ | +++ | NR | NR | NR | NR | NR |
| SGX393 | +++ | +++ | - | - | LCK | - | + |
| DC-2036 | +++ | +++ | NR | NR | ++ | NR | NR |